Association Study: The Aminopeptidase a Gene and Essential Hypertension

Morihiro Sano1, Nobuhiro Kuroi1, Tomohiro Nakayama2, Naoyuki Sato2, Yoichi Izumi3, Masayoshi Soma3

1Nihon University School of Medicine, Japan; 2Division of Receptor Biology, Advanced Medical Research Center, Japan; 3Second Department of Internal Medicine Nihon University School of Medicine, Tokyo, Japan

ABSTRACT

Aminopeptidase A (APA) cleaves the N-terminal aspartyl acid residue of angiotensin II (Ang II) to produce angiotensin III (Ang III). It has been reported that the APA knockout mouse exhibits elevated blood pressure. Therefore, the APA gene is thought to be a susceptibility gene for essential hypertension (EH). However, extensive studies have yet to define the relationship between the APA gene and EH. The aims of this study were to genotype some of the single nucleotide polymorphisms (SNPs) for the human APA gene and to perform a haplotype-based case-control study to further assess the association between and the APA gene and EH. We performed a genetic association study using SNPs in 227 EH patients and 221 age-matched normotensive (NT) individuals. Although the overall distribution of the genotype did not significantly differ between the EH and NT groups when the entire group of subjects were evaluated, the frequency of rs2290105 did differ between the two when just women were included in the analysis. The haplotype-based case-control analysis also revealed a significant difference between the women of the EH and NT groups. The A-T-A-C haplotype was significantly higher in the EH versus the NT group. These results suggest that rs2290105 and the A-T-A-C haplotype of the APA gene are genetic markers for EH, and that APA or a neighboring gene might be a susceptibility gene for EH. (Int J Biomed Sci 2005; 1: 16-22)

Keywords: essential hypertension; aminopeptidase A; single nucleotide polymorphism; haplotype; genetic; association study

INTRODUCTION

Angiotensinogen is cleaved by renin to generate angiotensin I (Ang I), which is further converted to angiotensin II (Ang II) by the angiotensin converting enzyme (ACE). Ang II is the fundamental peptide of the renin-angiotensin system (RAS), which induces constriction of blood vessels and increases the sodium and water retention, thus leading to an increase in blood pressure. Previous studies using mice that had a disruption of the genes responsible for the generation of angiotensin and the encoding of Ang II have provided information on the function of these genes. Aminopeptidase A (APA) cleaves the N-terminal aspartyl acid residue of Ang II to produce angiotensin III (Ang III). APA is the so-called angiotensinase and several studies have reported that purified APA functions as a hypotensive factor and that inhibitors of APA are hypertensive factors in vivo. A study that examined APA deficient mice found that the
baseline values for systolic blood pressure (SBP) and mean blood pressure (MBP) were higher in these animals. The blood pressure level for the mice with the targeted homozygous APA gene (APA-/-) was found to be significantly higher than that seen in the heterozygous (APA+/-) and wild types (APA+/+). These results suggest that APA is involved in blood pressure regulation, and that the metabolism of Ang II is a very important factor in the physiological regulation of blood pressure (1-5). Although the APA gene is thought to be a susceptibility gene for hypertension, there have been no studies examining that examined the association between the APA gene and essential hypertension (EH).

The APA gene is also listed as the negative primary endpoint (ENPEP) gene in the NCBI online database. The human APA gene is located on chromosome 4q25. This gene contains 18 exons, is interrupted by 17 introns, and has several single nucleotide polymorphisms (SNPs) (6, 7). High blood pressure or hypertension affects 25% of most adult populations and is an important risk factor for death from stroke, myocardial infarction and congestive heart failure. The majority of hypertensive cases are classified as primary and are referred to as essential hypertension (EH). EH is thought to be a multifactorial disease (8). However, there are a few reports that identify the susceptibility genes of EH as angiotensinogen (9), or angiotensin converting enzyme (10, 11).

The aims of this study were to genotype some of the single nucleotide polymorphisms (SNPs) for the human APA gene and to perform a haplotype-based case-control study to further assess the association between and the APA gene and EH.

METHODS

Subjects
This study included a group of 227 patients that were diagnosed with EH. A positive diagnosis required the patient to have a seated SBP above 160 mmHg and/or diastolic blood pressure (DBP) above 100 mmHg on 3 occasions within 2 months after their first medical examination. None of the patients were using anti-hypertensive medication and any of the subjects diagnosed with secondary hypertension were excluded. We also included 221 normotensive (NT) healthy individuals as controls. None of the NT participants had a family history of hypertension, and they all had SBP and DBP below 130 and 85 mmHg, respectively. A family history of hypertension was defined as prior diagnosis of hypertension in grandparents, uncles, aunts, parents or siblings. Both groups were recruited from the northern area of Tokyo, and informed consent was obtained from each individual as per the protocol approved by the Human Studies Committee of Nihon University (12).

Biochemical analysis
The methodology of the Clinical Laboratory Department of Nihon University Hospital was used to measure all plasma total cholesterol and HDL-cholesterol concentrations, and serum creatinine and uric acid concentrations (13).

Genotyping
Based on the allelic frequency data for the registered SNPs from the National Center for Biotechnology Information (NCBI) website and from Applied Biosystems-Celera Discovery System, we chose SNPs with minor allele frequencies of 20% or greater. This criterion was chosen since SNPs with a high frequency of the minor allele are very useful as genetic markers in genetic association studies.

We selected 4 SNPs in the introns of the human APA gene as markers for the genetic association experiment (Fig. 1). The minor allele frequencies for each of the SNPs among the Japanese subjects were >10% (screening estimate from the Celera Company), which indicates that they all should be effective genetic markers. All SNPs were confirmed using the dbSNP on the NCBI website and the Applied Biosystems-Celera Discovery System. The accession numbers were as follows: C_1731723_10

Figure 1. Organization of the human APA gene and location of the SNPs used for the association study. Closed black boxes indicate exons (coding region), closed white box indicate exons (non coding region) and lines indicate introns.
amInopeptIdase a gene and hypertens Ion
(no registration in the NCBI), rs9998275 (C_203475_10),
rs639194 (C_1285859_10), and rs2290105 (C_1285838_1) (Fig. 1). Genotypes were determined using Assays-on-Demand kits (Applied Biosystems, Branchburg, NJ) together with TaqMan○R PCR. When allele-specific fluorogenic probes hybridize to the template during the polymerase chain reaction (PCR), the 5’ nuclease activity of the Taq polymerase can discriminate alleles. Cleavage results in increased emission of a reporter dye that otherwise is quenched by the dye TAMRA. Each 5’ nuclease assay requires two unlabeled PCR primers and two allele-specific probes. Each probe is labeled with a reporter dye (VIC and FAM) at the 5’ end and TAMRA at the 3’ end. Amplification by PCR was carried out using TaqMan Universal Master Mix (PE Biosystems) in a 25 µl reaction volume with final total concentrations of 50 ng DNA, 700 nM primer, and 100 nM probe. Thermal cycling conditions consisted of 95°C for 10 min, and then 40 cycles of 92°C for 15 sec and 60°C for 1 min in a GeneAmp 9700 system.

All 96-well plates contained 80 samples of unknown genotype, six known allele 1 homozygotes, six known allele 2 homozygotes, and four reactions with reagents but no DNA. The homozygote and control samples without DNA were required for the SDS 7700 signal processing that is outlined in the TaqMan Allelic Discrimination Guide (PE Biosystems). Direct sequencing, single-stand conformation polymorphism (SSCP), or denaturing high pressure liquid chromatography were used to confirm control sample genotypes. PCR plates were read on the ABI 7700 instrument in the end-point analysis mode of the SDS version 1.6.3 software package (ABI). Genotypes were visually determined by comparison with the dye-component fluorescent emission data shown in the X-Y scatter-plot of the SDS software. Genotypes were also automatically determined by the signal processing algorithms in the software. Results of both scoring methods were saved to two output files for later comparison.

Haplotype-based case-control study

We performed haplotype analysis on the 4 SNPs. Based on the genotype data of the 4 genetic variations, the frequency of each haplotype was estimated using the expectation/maximization (EM) algorithm (14, 15). For the haplotype-based case-control study determinations, SNPAlyze version 3.2 was used (Dynacom Co., Ltd., Yokohama, Japan), which is available from their website at http://www.dynacom.co.jp/products/package/snpalyze/index.html.

Statistical analysis

Data are shown as mean ± SD. Differences between the EH and NT groups were assessed by analysis of variance (ANOVA) followed by a Fisher’s protected least significant difference (PLSD) test. Hardy-Weinberg equilibrium was assessed by a chi-square analysis. When the sizes of the expected values were small (below 2.0), the genotypes were combined (16). The overall distribution of the SNP alleles was analyzed by 2 × 2 contingency tables, and the distribution of the SNP genotypes between the EH patients and NT controls was tested using a 2-sided Fisher exact test and multiple logistic regression analysis. Statistical significance was established at p<0.05. The threshold value of the frequencies of the haplotypes included in the analysis was set to 1/2n (n: numbers of subjects in each group), as suggested by Excoffier and Slatkin (17). All haplotypes below the threshold value were excluded from the analysis. Overall distribution of haplotypes was analyzed using 2× m contingency tables with a value of p<0.05 considered to indicate statistical significance. The p value significance of each haplotype was determined by the chi-square analysis and permutation method using the software SNPAlyze version 3.2 (16).

RESULTS

Table 1 shows the clinical features for the EH patients and the NT controls. The SBP and DBP were significantly higher in the EH group as compared to that seen in the NT group. Age, body mass index (BMI), pulse rate, serum concentrations of creatinine and uric acid, and plasma concentrations of total cholesterol did not significantly differ between the two groups.

We performed an association study using 4 SNPs. Table 2 shows the genotype distributions of the 4 SNP variants and allelic frequencies. The overall distribution of the genotypes did not significantly differ between the two groups. However, there was a difference noted for the allelic frequency of the SNP rs2290105 between women in the EH and NT groups (p value=0.0409), with the allelic frequency of the minor allele in the EH group higher than that seen for the NT group.

The haplotype-based case-control study also documented significant differences between the women of the EH and NT groups (Table 3). There were significant differences for the results of the A-T-A-C haplotype, with this haplotype higher in the EH (42.6%) than in the NT group (28.8%).
DISCUSSIONS

APA cleaves the N-terminal aspartyl acid residue of Ang II to produce Ang III. An accumulation of Ang II leads to an increase in blood pressure. A previous animal study that examined the APA deficient mouse documented a relationship between hypertension and the APA gene (1). That study indicated that the SBP and DBP of the APA-/- mouse were significantly higher than those seen in the APA+/- mouse and the APA+/- mouse. Therefore, the metabolism of Ang II by APA is an important factor in the regulation of blood pressure (1-5, 18, 19). This suggests that the APA gene might be an indicator of disease susceptibility for EH. The use of SNPs is a valuable tool for association studies examining genomic markers. Since the SNPs consisted of 3 genotypes and 2 alleles, we were able to investigate the association between EH and the frequency of the genotype and the allele. We examined the association between the APA gene and EH using 4 SNPs of this gene. As there have been no previous association studies concerning the EH and APA gene, our study is the first one to attempt to determine this relationship.

In the present study, we found no differences in genotypic frequency between the EH and control groups. However, the allelic frequency of rs2290105 was significantly different between the women in the EH and NT groups. There have been previous reports on the APA knockout mouse, but these studies did not divide the mice into sexual groups (1). Therefore our data suggest that SNP rs2290105 might be a genetic marker for EH in women.

Genetic association studies have previously identified genes correlated with a gender-specific susceptibility to essential hypertension (20, 21). However, the reason for the present finding of a positive association between EH and SNP rs2290105 in women is unclear. There are other studies that have examined the association of the components of the renin-angiotensin system with gender-specific hypertension (22, 23). These observations highlight the potential importance of gender-dependent interactions between the genetic background and the expression of the hypertensive phenotype.

In conclusion, the present study is the first to examine the correlation between the human APA gene and EH. The present data indicate that the APA gene is a promising candidate for use as a genetic marker for EH in women.

Table 1. Characteristics of study participants

|                      | Total       |          |          |          |          |          |          |          |          |          |          |          |
|----------------------|-------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|                      | NT (n=221)  | EH (n=227)|          | NT (n=143)| EH (n=143)|          | NT (n=78) | EH (n=84) |          |          |          |          |
| Number of subjects   | 221         | 227      |          | 143      | 143      |          | 78       | 84       |          |          |          |          |
| Age (years)          | 51.1±8.4    | 51.0±5.5 | 0.924    | 51.7±6.1 | 50.8±5.6 | 0.185    | 49.9±11.5 | 51.4±5.3 | 0.288    |          |          |          |
| BMI (kg/m²)          | 23.4±2.9    | 23.7±2.6 | 0.240    | 23.6±2.8 | 23.8±2.4 | 0.461    | 23.0±3.1  | 23.5±2.9 | 0.297    |          |          |          |
| SBP (mmHg)           | 112.6±10.7  | 172.6±20.1| <0.001  | 113.1±10.1| 170.9±19.4| <0.001   | 111.6±11.7| 175.6±21.0| <0.001  |          |          |          |
| DBP (mmHg)           | 69.7±8.7    | 106.2±12.8| <0.001  | 70.5±8.1  | 107.5±12.6| <0.001   | 68.1±9.7  | 103.8±13.0| <0.001  |          |          |          |
| Pulse (beats/mm)     | 73.9±12.3   | 75.2±13.1 | 0.351    | 74.1±13.6 | 74.8±13.8 | 0.697    | 73.6±9.4  | 75.9±12.0 | 0.253    |          |          |          |
| Creatinine (mg/dl)   | 0.8±0.2     | 0.9±0.2  | 0.228    | 0.9±0.2  | 0.9±0.2  | 0.173    | 0.7±0.1  | 0.7±0.2  | 0.536    |          |          |          |
| Total cholesterol (mg/dl) | 203±43.9   | 209.3±39.0| 0.179    | 198.3±42.0| 202.5±37.0| 0.390    | 213.8±45.7| 220.2±39.9| 0.349    |          |          |          |
| HDL cholesterol (mg/dl) | 56.0±17.1  | 58.0±17.7| 0.257    | 53.4±15.2| 53.8±16.3| 0.867    | 60.4±19.3| 64.7±17.9| 0.167    |          |          |          |
| Uric acid (mg/dl)    | 5.8±4.7     | 5.6±1.6  | 0.488    | 6.0±1.4  | 6.1±1.5  | 0.450    | 5.5±7.7  | 4.7±0.14 | 0.335    |          |          |          |
| Alcohol consumption (%) | 60.8      | 67.8     | 0.126    | 72.8     | 81.6     | 0.066    | 33.9     | 38.6     | 0.569    |          |          |          |
| Smoking (%)          | 40.9        | 54.5     | 0.004    | 49.2     | 64.2     | 0.008    | 22.8     | 33.7     | 0.159    |          |          |          |

BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; HDL, High density lipoprotein; NT, Normotension; EH, Essential hypertension.
**Table 2. Genotype distribution in normotensives (NT) and patients with essential hypertension (EH)**

| Variants | Genotype | Total | | | Male | | | Female | | |
|---|---|---|---|---|---|---|---|---|---|
| | | NT | EH | P Value | NT | EH | P Value | NT | EH | P Value |
| **Number of participants** | 221 | 227 | | | 143 | 143 | | | 78 | 84 | |
| **Variants** | **Genotype** | | | | | | | | | |
| C_1731723-10 | A/A | 171 (0.777) | 173 (0.772) | | 114 (0.803) | 108 (0.735) | | 57 (0.731) | 65 (0.802) | |
| | A/T | 45 (0.205) | 50 (0.223) | | 25 (0.176) | 35 (0.245) | | 20 (0.256) | 15 (0.185) | |
| | T/T | 4 (0.018) | 1 (0.004) | 0.3608 | 3 (0.021) | 0 (0.000) | 0.0896 | 1 (0.013) | 1 (0.012) | 0.5536 |
| **Allele** | | | | | | | | | | |
| A | 387 (0.880) | 396 (0.884) | | 253 (0.891) | 251 (0.878) | | 134 (0.859) | 145 (0.895) | |
| T | 53 (0.120) | 52 (0.116) | 0.8397 | 31 (0.109) | 35 (0.122) | 0.6218 | 22 (0.141) | 17 (0.105) | 0.3267 |
| C_203475-1 | T/T | 173 (0.794) | 179 (0.821) | | 113 (0.807) | 115 (0.827) | | 60 (0.770) | 64 (0.810) | |
| | T/C | 42 (0.193) | 37 (0.170) | | 24 (0.171) | 22 (0.158) | | 18 (0.23) | 15 (0.190) | |
| | C/C | 3 (0.014) | 2 (0.009) | 0.7339 | 3 (0.021) | 2 (0.014) | 0.8603 | 0 (0.000) | 0 (0.000) | N.C |
| **Allele** | | | | | | | | | | |
| T | 388 (0.890) | 395 (0.906) | | 250 (0.893) | 252 (0.906) | | 138 (0.885) | 143 (0.905) | |
| C | 48 (0.110) | 41 (0.094) | 0.4336 | 30 (0.107) | 26 (0.094) | 0.5925 | 18 (0.115) | 15 (0.095) | 0.5547 |
| C_1285859-10 | G/G | 3 (0.014) | 3 (0.013) | | 3 (0.021) | 2 (0.014) | | 0 (0.000) | 1 (0.012) | |
| | G/A | 42 (0.191) | 36 (0.161) | | 24 (0.169) | 22 (0.155) | | 18 (0.231) | 14 (0.170) | |
| | A/A | 175 (0.795) | 185 (0.826) | 0.7035 | 115 (0.810) | 118 (0.831) | 0.8498 | 60 (0.769) | 67 (0.817) | 0.4092 |
| **Allele** | | | | | | | | | | |
| G | 48 (0.109) | 42 (0.094) | | 30 (0.106) | 26 (0.092) | | 18 (0.115) | 16 (0.098) | |
| A | 392 (0.891) | 406 (0.906) | 0.4488 | 254 (0.894) | 258 (0.908) | 0.5734 | 138 (0.885) | 148 (0.902) | 0.605 |
| C_1285838-1 | C/C | 48 (0.221) | 46 (0.204) | | 36 (0.257) | 27 (0.189) | | 12 (0.156) | 19 (0.232) | |
| | C/T | 85 (0.392) | 112 (0.498) | | 55 (0.393) | 74 (0.517) | | 30 (0.390) | 38 (0.463) | |
| | T/T | 84 (0.387) | 67 (0.298) | 0.0635 | 49 (0.350) | 42 (0.294) | 0.1007 | 35 (0.455) | 26 (0.305) | 0.133 |
| **Allele** | | | | | | | | | | |
| C | 181 (0.417) | 204 (0.453) | | 127 (0.454) | 128 (0.448) | | 54 (0.351) | 76 (0.463) | |
| T | 2353 (0.583) | 246 (0.547) | 0.2767 | 153 (0.546) | 158 (0.552) | 0.8856 | 100 (0.649) | 88 (0.537) | 0.0409 |

Significant difference in distribution; N.C.indicated the statistical result showing no calculating of chi-square in a contingency table,due to including a cell with the 0 number of sample.
ACKNOWLEDGMENTS

We would like to thank Mr. N. Sato and Ms. K. Sugama for their excellent technical assistance. This work was supported by a grant from the Ministry of Education, Science and Culture of Japan (High-Tech Research Center, Nihon University), a research grant from the Tanabe Biomedical Alumni Association of Nihon University School of Medicine, and a grant from the Tanabe Biomedical Conference, Japan.

REFERENCES

1. Mitsui T, Nomura S, Okada M, et al. Hypertension and angiotensin II hypersensitivity in aminopeptidase A deficient mice. Mol. Med. 2003; 9: 57-62.
2. Wright JW, Mizutani S, Murray CE, et al. Aminopeptidase-induced elevations and reduction in blood pressure in the spontaneously hypertensive rat. J. Hypertens. 1990; 8: 969-974.
3. Reaux A, Fournie-Zaluski MC, David C, et al. Aminopeptidase inhibitors as potential central antihypertensive agents. Proc. Natl. Acad. Sci. USA. 1999; 96: 13415-13420.
4. Kregel JF, Simon WM John, Laura L. Langenbach, Jeffrey B Hodgin, et al. Male-female differences in fertility and blood pressure in ACE deficient mice. Nature. 1995; 375: 146-148.
5. Nakashima Y, Ohno Y, Iikura A, et al. Possible involvement of aminopeptidase A in hypertension in spontaneously hypertensive rats (SHRs) and change of refractoriness in response to angiotensin II in pregnant SHRs. J. Hypertens. 2002; 20: 2233-2238.
6. Li Li, Qi Wu, Barry L. Barnoski BL, et al. High-Resolution Genetic Map of the Human Glutamyl Aminopeptidase. Genomics. 1997; 43: 380-383.
7. Nanus DM, Engelstein D, Gastl GA, et al. Molecular cloning of the human kidney differentiation antigen gp160: Human aminopeptidase A. Proc. Natl. Acad. Sci. USA. 1993; 90: 7069-7073.
8. Dominiczak AF, Negrin DC, Clark JS, et al. Genes and hypertension: from gene mapping in experimental models to vascular gene transfer strategies. Hypertension. 2000; 35: 164-172.
9. Sun Z, Cade R, Zhang Z, et al. Angiotensinogen gene knockout delays and attenuates cold-induced hypertension. Hypertension. 2003; 41: 322-327.
10. Scott H. Carlson, Suzanne Oparil, et al. Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice. Hypertension. 2002; 39: 214-218.
11. Williams GH. Genetic factors associated with volume-sensitive hypertension. Mol. Cell Endoc. 2004; 217: 41-44.
12. Nakayama T, Soma M, Mizutani Y, et al. A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: possible association with essential hypertension. Hypertens Res. 2002; 25: 395-401.
13. Nakayama T, Soma M, Hatake A, et al. Haplotype analysis of the prostacyclin synthase gene and essential hypertension. Hypertens Res. 2003; 26: 553-557.
14. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from complete data via the EM algorithm. J. R. Stat. Soc. 1977; 39: 1-22.
15. Hasimu B, Nakayama T, Mizutani Y, et al. Haplotype analysis of the human renin gene and essential hypertension. Hypertension. 2003; 41: 308-312.
16. Nakayama T, Soma M, Takahashi Y, et al. Association analysis of CA repeat polymorphism of the endothelial nitric oxide synthase gene with essential hypertension in Japanese. Clinical Genetics. 1997; 51: 26-30.
17. Excoffier L, Slatkin M. Maximum-kikelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol. 1995; 12: 921-927.
18. Ahmad S, Ward PE. Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J. Pharmacol. 1990; 252: 643-650.
19. Wright JW, Mizutani S, Murray CE, et al. Aminopeptidase induced elevations and reductions in blood pressure in the spontaneously hypertensive rat. J. Hypertens. 1990; 8: 69-74.
20. Ono K, Mannami T, Iway N. Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. J. Hypertens.
2003; 21: 1497-503.

21. Coatmellec-Taglioni G, Dausse JP, Giudicelli Y, et al. Gender difference in diet-induced obesity hypertension: implication of renal alpha2-adrenergic receptors. Am. J. Hypertens. 2002; 15 (2 Pt 1): 143-149.

22. Kim HS, Lee G, John SW, et al. Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc. Natl. Acad. Sci. USA. 2002; 99: 4602-4607.

23. Sagnella GA, Rothwell MJ, Onipinla AK, et al. A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism. J. Hypertens. 1999; 17: 657-664.